Reprogramming B cells into durable, in-body factories for the medicines patients are missing.
ON THE RECORD // Be Biopharma, Inc. - a clinical-stage biotech at 1 Kendall Square, Cambridge, led by CEO Joanne Smith-Farrell, Ph.D.
Every human body already contains a manufacturing marvel most drug developers walked past for decades. A single B cell, once it matures into a plasma cell, can secrete thousands of protein molecules per second - at steady levels, and it can persist in the bone marrow for years. Be Biopharma, the Cambridge company that styles itself "Be Bio," looked at that biology and asked a deceptively simple question: what if you could program that factory to make exactly the protein a patient's body cannot?
That question is the seed of an entire proposed modality the company calls Engineered B Cell Medicines, or BCMs. Where antibody drugs and standard gene therapies deliver or replace a protein from the outside, Be Bio's approach edits a person's own cells so the medicine is produced continuously from within. The pitch is durability: one treatment that could keep working for a long time, that engrafts without the harsh preconditioning many cell therapies require, and that could - in principle - be re-dosed.
It is an ambitious wager, and Be Bio has been candid that turning a platform into an approved drug is a long, humbling road. But the company has assembled the money, the manufacturing partners, and the scientific pedigree to take the swing.
B cells are nature's exquisite medicine factories - manufacturing proteins to fight disease and maintain health.
What Be Bio does. It uses precision genome editing to insert a therapeutic gene into primary human B cells, then differentiates them into plasma cells that secrete a chosen protein. The result is designed to behave like a living, long-lasting drug depot rather than a pill or an infusion schedule.
Who it is for. Ultimately, patients with hemophilia B, rare genetic and metabolic diseases such as hypophosphatasia, and - the company argues - a wider set of conditions where a missing or under-produced protein drives the disease. In the near term, its stakeholders are clinical investigators, regulators, strategic pharma partners and investors.
The problem it solves. Many protein-deficiency diseases are managed today with frequent, lifelong infusions or injections. Existing gene therapies can be one-and-done but are hard to re-dose and sometimes require conditioning regimens. Be Bio is aiming for the middle ground: durable protein production that can also be topped up.
Why it is different. The core differentiator is the cell type. By betting on B cells rather than T cells or viral vectors alone, Be Bio is targeting sustained protein secretion, bone-marrow engraftment without preconditioning, and potential redosability - a combination its incumbents struggle to offer all at once.
Be Bio's platform is the engine; its named programs are the first two cars off the line. Bars below are illustrative of stage progression, not precise timelines.
Precision-edited human B cells become plasma cells that secrete therapeutic protein, engraft without preconditioning, persist for years, and are potentially re-dosable.
Est. 2020Inserts the human Factor IX gene into B cells to continuously produce clotting factor for hemophilia B. FDA Fast Track; tested in the Phase 1/2 BeCoMe-9 trial.
Clinic entry 2024Designed to produce alkaline phosphatase for hypophosphatasia, a rare metabolic bone disorder. Named a development candidate on the path to the clinic.
2025The model. Be Bio is a venture-funded, pre-revenue therapeutics developer. It converts capital into R&D, aiming to create value through clinical proof-of-concept, partnerships and licensing, and - eventually - regulatory approval and commercialization. Data providers peg annual revenue near $5M, which for a clinical-stage biotech typically reflects grants or collaboration income rather than product sales.
Where it fits. Be Bio sits in the fast-moving cell and gene therapy landscape alongside AAV gene-therapy players in hemophilia (such as CSL Behring/uniQure, Pfizer and BioMarin), CAR-T and engineered-cell companies, and next-generation cell-engineering platforms. Traditional factor-replacement and antibody drugs remain the incumbent standard of care. Be Bio's claim to distinctiveness is the B cell itself - and the durability, engraftment and redosability it is built to deliver.
The reality check. In 2026 the company ended its Phase 1/2 BeCoMe-9 study of BE-101 as a strategic business decision - notably, not because of a safety signal - after enrolling five of a planned 24 patients. In a tight biotech funding market, knowing when to pause a program is part of the discipline of building a durable company.
Founded out of Seattle Children's Research Institute and Longwood Fund with a $52M Series A to develop B cells as medicines.
Strategic collaboration with National Resilience to manufacture engineered B cells for the rare disease pipeline.
FDA Fast Track and IND clearance, an $82M raise, and the first participant dosed in the BeCoMe-9 hemophilia B trial.
Closed a Series C and transitioned to a multi-program, clinical-stage company advancing BE-101 and BE-102.
Ended the Phase 1/2 study of BE-101 as a strategic business decision, unrelated to safety, after enrolling five patients.
B cell engineering scientists from Seattle Children's Research Institute whose research became Be Bio's foundational technology, commercialized with Longwood Fund in 2020.
Chief Executive Officer, steering Be Bio from single-asset startup to a multi-program, clinical-stage company. "We are well-equipped to advance our two lead programs," she said of the Series C.
Strategic collaborator (since 2022) building the capability to produce engineered B cells at scale - the make-or-break challenge for any cell therapy.
Corporate backers alongside ARCH, Atlas, RA Capital, Alta, Longwood and Nextech - an investor roster that reads like a life-science who's who.